Tesamorelin
N-terminally modified GHRH(1–44) amide analogue, used in GHRH-receptor research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-TESA-5 · ≥99% (see COA) · Lyophilised powder
Note: Salt form (e.g. acetate or TFA) and net peptide content to be confirmed from the supplier COA. Authorised as a medicine outside the UK; the client's solicitor has advised that it holds no UK marketing authorisation.
Tesamorelin overview
Tesamorelin is the full 44-residue human growth-hormone-releasing hormone sequence with a trans-3-hexenoyl group on the N-terminal tyrosine. It is supplied as a lyophilised solid for in-vitro laboratory research.
Tesamorelin research background
Evidence status: Findings summarised here include clinical-trial data; this compound has a regulatory status as a medicine in some countries outside the UK, which does not apply to this research-grade product. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH, 44 amino acids) with an N-terminal trans-3-hexenoyl modification. In the US it has a marketing authorisation for reducing excess abdominal fat in people with HIV-associated lipodystrophy. It does not have a UK marketing authorisation, and this research-grade product is not a medicine [1].
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
- GHRH-receptor agonism, increasing endogenous GH and IGF-I [2].
Research areas & model types
Human clinical research status
Safety observations reported in studies
- Reviews note the lack of long-term safety data as a limitation [1].
Known limitations
- Most trials were in specific HIV populations.
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- Researchers have proposed studying GHRH analogues in physical function and brain-ageing research [5][6].
Registered clinical studies (ongoing or unpublished)
- NCT06554717 — Phase 2 TRIUMPH trial of tesamorelin as an adjunct to exercise in HIV (sponsor: Massachusetts General Hospital); protocol published [6].
- NCT03150511 — Phase 2 study in peripheral nerve injury (sponsor: Johns Hopkins University).
Registry entries checked on ClinicalTrials.gov on 24 October 2026; status as listed by the sponsor. Registration does not imply results or efficacy.
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012. PubMed 22298602 · doi:10.1345/aph.1Q629
- Falutz J, Allas S, Blot K et al.. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PubMed 18057338 · doi:10.1056/NEJMoa072375
- Stanley TL, Feldpausch MN, Oh J et al.. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. PubMed 25038357 · doi:10.1001/jama.2014.8334
- Stanley TL, Fourman LT, Feldpausch MN et al.. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019. PubMed 31611038 · doi:10.1016/S2352-3018(19)30338-8
- Baker LD, Barsness SM, Borson S et al.. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012. PubMed 22869065 · doi:10.1001/archneurol.2012.1970
- Erlandson KM, Gustafson L, Johnson JE et al.. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026. PubMed 42419889 · doi:10.1136/bmjopen-2026-120740
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
AOD9604
CJC-1295 (with DAC)
CJC-1295 (without DAC)
CJC-1295 (without DAC) / Ipamorelin blend
Browse similar compounds: Endocrine & receptor-signalling research peptides or the full catalogue.